e-Edition
Obituaries
Photo Gallery
Magazines
News Crew
Paywall Login
Login to Comment
Register
December 15th, 2015
Menu
Home
News
Sports
Business
Entertainment
Federal Election
Classifieds
Life
Commentary
Contact
Local News
Provincial News
National News
World News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amneal Pharmaceuticals Inc
(NY:
AMRX
)
N/A
UNCHANGED
Last Price
Updated: 7:00 PM EST, Dec 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amneal Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
May 22, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at Upcoming Investor Conference
May 22, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports First Quarter 2024 Financial Results
May 03, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
April 24, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
April 16, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report First Quarter 2024 Results on May 3, 2024
April 10, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
March 28, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
March 25, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
March 01, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
February 27, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
6 reasons to buy Teva Pharmaceuticals stock sooner than later
February 26, 2024
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why
Via
MarketBeat
Topics
Lawsuit
Exposures
Financial
Legal
Amneal to Participate at Upcoming Investor Conference
February 13, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
January 31, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
January 10, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
January 04, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces Move to Nasdaq
December 15, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
December 07, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
December 01, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at Upcoming Investor Conferences
November 03, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
October 23, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
October 12, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report Third Quarter 2023 Results on November 7, 2023
October 05, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
September 06, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives First Product Approval in China
September 06, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
September 06, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India
August 29, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
August 25, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
August 24, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Twitter
Facebook
YouTube
Tumblr